Table 1 Baseline Clinical Characteristics
Variables | Overall population | Matched population | ||||
|---|---|---|---|---|---|---|
PCB (n = 32) | Non-PCB (n = 74) | p | PCB (n = 25) | Non-PCB (n = 25) | p | |
Age, years* | 70.8 ± 7.2 | 76.7 ± 9.3 | 0.320 | 71.9 ± 7.5 | 71.5 ± 8.9 | 0.864 |
Male sex* | 20 (62.5) | 48 (64.9) | 0.816 | 17 (68.0) | 17 (68.0) | 1.000 |
Body mass index, kg/m2* | 23.8 ± 3.7 | 23.3 ± 3.5 | 0.531 | 23.4 ± 3.7 | 23.6 ± 2.4 | 0.770 |
Hypertension* | 31 (96.9) | 64 (86.5) | 0.167 | 24 (96.0) | 25 (100.0) | 1.00 |
Diabetes mellitus* | 26 (81.3) | 49 (66.2) | 0.163 | 19 (76.0) | 17 (68.0) | 0.754 |
Dyslipidemia* | 15 (46.9) | 37 (50.0) | 0.768 | 11 (44.0) | 13 (52.0) | 0.571 |
Current smoker* | 8 (25.0) | 15 (20.3) | 0.614 | 5 (20.0) | 5 (20.0) | 1.000 |
Chronic kidney disease* | 11 (34.4) | 32 (43.2) | 0.391 | 9 (36.0) | 7 (28.0) | 0.762 |
Hemodialysis* | 2 (6.3) | 11 (14.9) | 0.336 | 2 (8.0) | 2 (8.0) | 1.000 |
Rutherford class* | 0.067 | 1.000 | ||||
2/3 | 31 (96.9) | 62 (83.8) | 24 (96.0) | 25 (100.0) | ||
4 | 1 (3.1) | 7 (9.5) | 1 (4.0) | 0 (0.0) | ||
5 | 0 (0.0) | 5 (6.8) | 0 (0.0) | 0 (0.0) | ||
Ankle brachial index | 0.63 ± 0.12 | 0.60 ± 0.15 | 0.375 | 0.62 ± 0.13 | 0.61 ± 0.11 | 0.792 |
Medication at treatment of ISR | ||||||
Aspirin | 29 (90.6) | 67 (90.5) | 1.000 | 22 (88.0) | 24 (96.0) | 0.609 |
P2Y12 antagonist | 21 (65.6) | 52 (70.3) | 0.637 | 16 (64.0) | 13 (52.0) | 0.567 |
Cilostazol | 15 (46.9) | 30 (40.5) | 0.546 | 13 (52.0) | 13 (52.0) | 1.000 |
Oral anticoagulant | 2 (6.3) | 14 (18.9) | 0.140 | 2 (8.0) | 5 (20.0) | 0.417 |